Introduction
============

Micro RNAs (miRNAs) are an important subclass of small regulatory RNA. They are present in virtually all kingdoms of life and involved in crucial metabolic functions. Their main function is the downregulation of a target transcript via complementary base pairing. In general, these transcriptional modifiers are located within the synthesizing cell but are also able to translocate via gap junctional cell-cell contacts or exosomal release ([@B37]; [@B79]). They influence a variety of cellular processes such as autophagy, differentiation and stress-response ([@B77]; [@B38]; [@B49]; [@B69]; [@B24]). Moreover, miRNAs have been found to contribute to pathological conditions, for example cancer development or autoimmunity ([@B72]). In the case of neurodegenerative diseases such as Parkinson's disease (PD) or Alzheimer's disease (AD), miRNA patterns of patients differ from healthy control groups. Recent examples for differential miRNA abundances are selective upregulations of let-7b and let-7e in cerebrospinal fluid (CSF) within AD patients ([@B14]), or miR-24 and miR-205 that distinguished PD patients from controls in a comparably small cohort ([@B46]).

Many characteristics are shared between AD and PD, such as pathological mechanisms (e.g., protein aggregation) or genetic variants. Therefore, it has been postulated that these diseases may share similar alterations that could trigger comparable pathological pathways. Using literature mining of GWAS studies, regulatory networks enriched with AD- and PD-associated genes could be identified ([@B58]; [@B66]). Nowadays miRNAs can be extracted from nearly every kind of body fluid or type of tissue ([@B71]), providing easy access to this information. Interestingly, it was already demonstrated in 2009 that miRNAs from feces might serve as biomarkers for colon cancer and active ulcerative colitis ([@B2]). This has been confirmed by many subsequent studies ([@B41]; [@B36]; [@B59]; [@B73]).

miRNAs within feces usually originate from exfoliated cells of the host's gastrointestinal tract, but also possibly from food ([@B35]). Evidence for this was acquired by feeding mice with RNA obtained from *Brassica oleracea*. Exogenous plant miRNA was detectable within the animal's serum, feces and tissues for up to 72 h ([@B40]). Interestingly, not only epithelial cells in the walls of the gut lumen are affected by the excreted or ingested miRNAs, but also the host's microbiome. Liu and colleagues reported in 2016 that host miRNA can enter bacterial cells and regulate growth behavior and certain bacterial gene transcripts ([@B57]). In their study, *Fusobacterium nucleatum* cultured with human miR-515-5p showed an increased ratio of 16S rRNA/23S rRNA transcripts.

A different approach showed that it is possible to change the microbiome through miRNAs *in vivo*. [@B16] infected miR-146a-deficient mice with *Listeria monocytogenes*. This led to a differently developed gut microbiome and an increased infection tolerance against *Listeria monocytogenes* compared to wild type mice.

With respect to neurodegenerative diseases, the connection between host and gut microbiome has shifted increasingly into the focus of research ([@B63]; [@B5]; [@B9]; [@B70]; [@B4]; [@B6]; [@B22]). The contribution of altered miRNA patterns toward these changes and their possible impact on pathology is still an open question. Until now, miRNA analyses of feces collected from patients suffering from neurodegenerative diseases are rather scarce. However, consistent changes of miRNAs (miR-16, miR-21, mir-34a and miR-222) have been detected in both plasma and feces derived from the same individual ([@B67]).

This encouraged us to conduct the following two-step analysis. The first step was the collection of common miRNA patterns within blood and tissue from AD and PD patients, based on the data from seven studies. The second step consisted in identifying potential bacterial target sites for the selected miRNAs.

Materials and Methods {#s1}
=====================

Differentially Expressed-miRNAs
-------------------------------

Lists of differentially expressed miRNAs in AD and PD were aggregated from seven different studies (see [Supplementary Table S1](#TS1){ref-type="supplementary-material"}, [@B47]; [@B64]; [@B8]; [@B27]; [@B43]; [@B44]; [@B15]; [@B61]). The lists were filtered after a *p*-value cut-off of 5%; the respective micro-RNAs were split in AD, PD up- and downregulated. The resulting lists were used as an input for the target scan analysis.

Target Scan Analysis
--------------------

Target Scan analysis for potential targets of the micro-RNAs on the human gut metagenome was performed with miRanda (v3.3a; [@B19]). Parameters for target filtering were: -strict -go -2 -ge -8 -sc 150.00 -en -25.00 -scale 3.00. For the target scan, the gut metagenome database was created based on the work by [@B56]. However, we only used species with a complete annotation available via the NCBI RefSeq ([@B52]). Afterwards, the miRanda hits were grouped by micro-RNA family affiliation as well as by organism and aggregated on family level. Afterwards, the miRanda output was parsed using a custom bash script. We intersected the miRanda output with the annotation file for each respective species and kept all protein IDs that were targeted ([Supplementary Table S5](#TS5){ref-type="supplementary-material"}). The protein IDs for the hits were used for the subsequent target analysis.

GO-Terms for Human miRNA Targets on Bacterial Genes
---------------------------------------------------

GO terms were retrieved via GORetriever ([@B48]). The dataset was reduced using the GOSlimViewer with the metagenomic GOSlim set. Enrichment was done with Blast2GO ([@B23]).

Results
=======

miRNAs Differentially Expressed in AD and PD
--------------------------------------------

In the first step of our meta-analysis, 346 miRNAs were aggregated from 7 studies evaluating miRNAs in AD and PD (see [Supplementary Tables S1](#TS1){ref-type="supplementary-material"}, [S8](#TS8){ref-type="supplementary-material"}). The miRNAs were grouped into different categories, according to their up- or downregulation and their role in AD or PD. We were particularly interested in miRNAs being differentially expressed in both diseases. [Figure 1](#F1){ref-type="fig"} summarizes the number of miRNAs being up- or downregulated in both, AD and PD patients, compared to healthy controls (*p*-value \< 0.5). Out of 95 miRNAs upregulated in AD patients, 8 miRNAs were upregulated in patients with PD as well (see also [Table 1](#T1){ref-type="table"}). The total number of upregulated miRNAs in PD compared to controls is 82. The comparison of downregulated miRNAs in both, AD patients (134 miRNAs) and PD patients (84 miRNAs), reveals a number of 35 expressed miRNAs (see also [Table 2](#T2){ref-type="table"}). Interestingly, 5 miRNAs found to be upregulated in AD were significantly downregulated in PD. Vice versa, 4 miRNAs that were found to be downregulated in AD were upregulated in PD. All candidates are listed in the [Supplementary Table S2](#TS2){ref-type="supplementary-material"}.

![Venn-Diagram of miRNAs being differentially expressed in patients suffering from AD and PD versus healthy controls. The overlaps summarize miRNAs being detected in both conditions.](fnins-13-00113-g001){#F1}

###### 

Commonly upregulated miRNAs in AD and PD.

  Identifier         Pathway Analysis Results                                                           AD reference   PD reference
  ------------------ ---------------------------------------------------------------------------------- -------------- --------------
  hsa-miR-30c-2-3p                                                                                      [@B8]          [@B8]
  hsa-miR-592                                                                                           [@B8]          [@B8]
  hsa-miR-148a-3p                                                                                       [@B8]          [@B8]
  hsa-miR-30a-5p                                                                                        [@B8]          [@B8]
  hsa-miR-190a-5p                                                                                       [@B8]          [@B8]
  hsa-miR-769-3p                                                                                        [@B8]          [@B68]
  hsa-mir-378c^∗^    Biofilm formation (*P. aeruginosa*), Bacterial Secretion Pathway, Quorum Sensing   [@B8]          [@B64]
  hsa-mir-485-5p                                                                                        [@B27]         [@B27]
                                                                                                                       

∗

miRNAs that are involved in one of the analyzed pathways (see Results: Pathway analysis)

.

###### 

Commonly downregulated miRNAs in AD and PD.

  Identifier                Pathway Analysis Results                                                     AD reference    PD reference
  ------------------------- ---------------------------------------------------------------------------- --------------- ---------------
  hsa-miR-124-3p                                                                                         [@B8]           [@B8]
  hsa-miR-127-3p                                                                                         [@B8]           [@B8]
  hsa-miR-128-1-5p                                                                                       [@B8]           [@B8]
  hsa-miR-128-3p                                                                                         [@B8]           [@B8]
  hsa-miR-1299^∗^           Biofilm formation (*V. cholerae*)                                            [@B8]           [@B8]
  hsa-miR-132-3p                                                                                         [@B8]           [@B8]
  hsa-mir-132-5p^∗^, ^∗∗^   Biofilm formation (*E. coli*), Bacterial Secretion Pathway, Quorum Sensing   [@B8]; [@B27]   [@B8]; [@B27]
  hsa-miR-134-5p                                                                                         [@B8]           [@B8]
  hsa-mir-136-3p                                                                                         [@B8]; [@B27]   [@B8]; [@B27]
  hsa-miR-136-5p^∗^         Biofilm formation (*E. coli*), Quorum Sensing                                [@B8]           [@B8]
  hsa-miR-138-1-3p                                                                                       [@B8]           [@B8]
  hsa-miR-138-5p^∗^         Biofilm formation (*E. coli*), Quorum Sensing                                [@B8]           [@B8]
  hsa-miR-139-3p                                                                                         [@B8]           [@B8]
  hsa-miR-139-5p                                                                                         [@B8]           [@B8]
  hsa-miR-150-5p                                                                                         [@B44]          [@B8]
  hsa-mir-151                                                                                            [@B27]          [@B27]
  hsa-mir-16-2                                                                                           [@B27]          [@B27]
  hsa-miR-212-3p                                                                                         [@B8]           [@B8]
  hsa-mir-29c^∗∗^                                                                                        [@B27]          [@B27]
  hsa-miR-323a-3p                                                                                        [@B8]           [@B8]
  hsa-miR-323b-3p                                                                                        [@B8]           [@B8]
  hsa-mir-331-5p                                                                                         [@B27]          [@B27]
  hsa-miR-370-3p                                                                                         [@B8]           [@B8]
  hsa-miR-376a-5p                                                                                        [@B8]           [@B8]
  hsa-miR-377-5p                                                                                         [@B8]           [@B8]
  hsa-miR-383-5p                                                                                         [@B8]           [@B8]
  hsa-miR-409-3p                                                                                         [@B8]           [@B8]
  hsa-miR-431-3p                                                                                         [@B8]           [@B8]
  hsa-miR-433-3p                                                                                         [@B8]           [@B8]
  hsa-miR-485-5p                                                                                         [@B8]           [@B8]
  hsa-miR-539-5p                                                                                         [@B8]           [@B8]
  hsa-miR-744-3p                                                                                         [@B8]           [@B8]
  hsa-miR-760                                                                                            [@B8]           [@B8]
                                                                                                                         

∗

miRNAs that are involved in one of the analyzed pathways (see Results: Pathway analysis);

∗∗

miRNAs that have been chosen for selective analysis (see Results: Selection of miRNAs)

.

Crosstalk Between miRNA and Microbiome Composition
--------------------------------------------------

To investigate a potential crosstalk between bacteria and host miRNAs, as illustrated in [Figure 2](#F2){ref-type="fig"}, we aimed to detect potential target sites of miRNAs within bacterial genomes. All 346 miRNAs were screened against 207 bacterial reference genomes, taken from a database of human gut metagenomic samples (listed in [Supplementary Tables S3](#TS3){ref-type="supplementary-material"}, [S4](#TS4){ref-type="supplementary-material"}). The most prevalent bacterial phyla in the database were Firmicutes, Proteobacteria and Bacteroidetes. The target scan using miRanda (v3.3a; [@B19]) revealed 20363 potential binding sites on the 205 bacterial reference genomes for 327 unique miRNAs. It is worth mentioning that each miRNA has the potential to target multiple locations and vice versa; a particular region can be associated to multiple miRNAs. Interestingly, eleven out of the selected miRNAs were connected to over 200 protein identifiers. Here, the miRNA hsa-miR-1226-5p had the maximum amount of potential target sites with 1109 hits predicted by miRanda, followed by hsa-miR-1183 with 780, hsa-miR-4767 with 683 and hsa-miR-3916 with 604 possible binding sites.

![Hypothesized crosstalk between the host miRNAs being released into the gut lumen and the gut microbiome.](fnins-13-00113-g002){#F2}

The bar plot in [Figure 3A](#F3){ref-type="fig"} shows the number of different species per phylum of the reference database. The largest phylum with the highest number of different species is Firmicutes, followed by Proteobacteria and Bacteroidetes. The correlation between total miRNA hits, as predicted by miRanda, and the length of the reference genomes per taxonomy identifier is shown in [Figure 3B](#F3){ref-type="fig"}. As expected, the number of hits grows with genome length. The outlier on the top right is *Streptomyces sparsogenes*. [Figure 3C](#F3){ref-type="fig"} shows the miRNA match per phylum for the complete set of miRNAs. Similar to the reference database, Firmicutes, Proteobacteria and Bacteroidetes were the most prominent taxa. In [Figure 3D](#F3){ref-type="fig"} the number of unique proteins targeted in the respective phyla are given. It is evident here that Firmicutes and Proteobacteria have the most hits. Compared to the hits of unique miRNAs, the ratio of unique proteins that were targeted between Firmicutes and Proteobacteria is shifted toward the latter. Moreover, Synergistetes were targeted at a much higher frequency. Upon closer examination, the counts for protein identifiers in Actinobacteria were mostly composed of *Streptomyces sparsogenes* targeted by hsa-miR-4767. This combination accounted for 203 of 683 hits.

![General results of the target scan. **(A)** The species composition of our genomic reference database. **(B)** The number of miRNA hits plotted against the reference genome length of the different phyla. **(C)** The number of miRNAs that revealed hits with a bacterial organism is shown per phylum, and **(D)** the number of unique protein IDs, which were predicted to have putative target sites for miRNAs, in different phyla. The colors refer to different phyla. The legend for all graphs is given beneath the lower plots.](fnins-13-00113-g003){#F3}

Investigation of Potential Targets by Screening KEGG Pathways
-------------------------------------------------------------

Because several bacterial biofilm components (like functional amyloids or bacterial endotoxins) are linked to the aggravation of symptoms in AD and PD, we screened a number of reference pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) Orthology (KO) Database for proteins that were targeted by the constructed miRNA set ([@B51]; [@B30]; [@B32], [@B31]). Pathways of particular interest were the bacterial secretion system, lipopolysaccharide biosynthesis and the biofilm formation pathway of three different species.

It is worth mentioning that only protein IDs mapped to a KO pathway could be considered in the analysis.

Furthermore, several species were mapped to different pathways simultaneously.

### Bacterial Secretion System

The bacterial secretion system is mainly responsible for shuttling proteins across cell membranes. Furthermore, bacterial secretion is linked to virulence and interaction with the host's immune system. Especially in the case of AD, latent infection is increasingly recognized as a potential cause for the disease ([@B26]; [@B21]).

[Figure 4](#F4){ref-type="fig"} shows an overview of the bacterial secretion system from KEGG. Among the successfully mapped identifiers, mostly Type II secretion pathway proteins were targeted. Those belong primarily to the Sec-SRP class, that is shown in [Figure 4](#F4){ref-type="fig"}. The targeted identifiers (gspE, secA, secF, secG, secY, SRP54, ftsY, tatA, virB8, virD4, yidC) revealed an overlap with the genomic positions of 20 original protein IDs for 16 miRNAs on 19 taxonomic units ([Supplementary Table S5](#TS5){ref-type="supplementary-material"}). miRNA hsa-miR-3180-5p targeted three different proteins (secA, secF and gspE) in three different species (*Ruminococcus champanellensis* 18P13 = JCM 17042, *Pseudomonas* sp. ADP, *Klebsiella* sp. 4_1\_44FAA). hsa-miR-132-5p and hsa-miR-1183 targeted two protein IDs in two different species, respectively.

![Bacterial Secretion System from KEGG. Proteins encoded by bacterial genome regions that revealed miRNA target matches are colored in pink.](fnins-13-00113-g004){#F4}

### Lipopolysaccharide Biosynthesis

Bacterial lipopolysaccharides (LPS) are known to trigger a widespread host immune system response as well as neuroinflammation ([@B54]; [@B39]). Increased LPS levels were found in both, the bloodstream and the brain of AD patients ([@B75]; [@B74]). Assessment of pathway members of the bacterial lipopolysaccharide biosynthesis pathway that harbor putative miRNA binding sites led to six hits, namely: lpxA, lpxL, waaC, kdsC, gmhB, gmhD. In [Figure 5](#F5){ref-type="fig"}, the lipopolysaccharide biosynthesis is shown with protein hits colored in pink.

![Lipopolysaccharide Biosynthesis from KEGG. Proteins encoded by bacterial genome regions that revealed miRNA target matches are colored in pink.](fnins-13-00113-g005){#F5}

From the list of targeting miRNAs, those six proteins had 7 hits on 6 taxonomic entries, belonging to the Bacteroidetes and the Proteobacteria. Among all hits, only hsa-miR-3180-5p targeted the same protein in two different *Klebsiella* species, namely lpxL ([Supplementary Table S5](#TS5){ref-type="supplementary-material"}).

### Biofilm Formation

Functional amyloids, such as curli, are often components of bacterial biofilms ([@B62]) which have the potential to change the virulence and invasiveness of bacteria. Furthermore, it has been shown that biofilm components were able to increase amyloidogenesis, even when only fed to rats ([@B10]). We examined this pathway class via KEGG pathway mapping for the organism *Escherichia coli* (see [Table 3](#T3){ref-type="table"} and [Figure 6](#F6){ref-type="fig"}) as well as for *Vibrio cholerae* ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}) and *Pseudomonas aeruginosa* ([Supplementary Figure S2](#FS2){ref-type="supplementary-material"}).

###### 

List of mapping proteins in biofilm formation of *Vibrio cholerae, Escherichia coli*, and *Pseudomonas aeruginosa*.

  *Vibrio cholerae*   *Escherichia coli*   *Pseudomonas aeruginosa*
  ------------------- -------------------- --------------------------
  CysE                PYG                  ImpH
  WecB                GlgA                 Hcp
  PaaK                GlgC                 
  GspE                CsgD                 
  WecC                RcsB                 
  RpoN                                     
  Fis                                      
                                           

![Biofilm Formation Pathway using KEGG pathway mapping for *E. coli*. Proteins encoded by bacterial genome regions that revealed miRNA target matches are colored in pink.](fnins-13-00113-g006){#F6}

Interestingly, CsgD, a master regulator of biofilm formation and the synthesis of curli fimbriae ([@B7]), was targeted on *Klebsiella* sp. 4_1\_44FAA. Since this is a multispecies protein for Enterobacteriaceae, it also maps in the *E. coli* pathway map. Other proteins targeted are PYG, GlgA and GlgC, as shown in [Figure 6](#F6){ref-type="fig"}. All these proteins are involved in the glycogen biosynthesis. For the *Vibrio cholerae* pathway map ([Supplementary Figure S1](#FS1){ref-type="supplementary-material"}), seven proteins offered target sites for miRNAs in the target scan. WecC is involved in the biosynthesis of polysaccharides. RpoN seems to be involved in bacterial virulence ([@B33]). Fis is involved in flagellar movement and controls virulence-associated genes ([@B29]). GspE is a protein involved in the general secretion pathway. PaaK is associated with phenylactetat-CoA ligase, an enzyme involved in energy metabolism. WecB seems to be involved in capsule precursor proteins ([@B65]). miRNA targets within *Pseudomonas aeruginosa* were ImpH and Hcp (for pathway overview see [Supplementary Figure S2](#FS2){ref-type="supplementary-material"}). ImpH is involved in transport through membranes, while Hcp seems to be involved in the interaction of *E. coli* with human endothelial cells ([@B76]).

Target Scan Results for a Subset of miRNAs
------------------------------------------

To investigate the impact of individual miRNAs on potential bacterial targets, we shortlisted six miRNAs based on systematic literature research, as well as those two miRNAs who had the highest amount of hits, according to the target scan.

mir-132, a well-known mediator of neurodegenerative diseases ([@B28]; [@B17]), targeted 32 different species in 4 different phyla. [Figure 7](#F7){ref-type="fig"} shows the miRNA hits on annotated proteins per phylum. It becomes evident that, compared to the other phyla, Bacteroidetes are more frequently targeted, despite the fact that they are only the third largest phylum in the overall taxonomic composition of the database. Conversely, Firmicutes, representing the largest taxonomic group in the database were targeted at a much lower frequency.

![Number of hits from specific miRNAs per phylum. The bar plots show the number of hits from miRNAs **(A)** hsa-miR-132, **(B)** hsa-miR-125b, **(C)** hsa-miR-146a, **(D)** hsa-miR-29a, **(E)** hsa-miR-29b and **(F)** hsa-miR-29c counted for different phyla. The legend can be found at the bottom. The colors refer to different phyla.](fnins-13-00113-g007){#F7}

The scan for the mir-29 family revealed that they all mostly target Firmicutes, Proteobacteria and Bacteroidetes at the same ratio. Mir-29b, with 162 species in 6 phyla, had the highest number of predicted target sites. miR-125b had most hits on the phylum Proteobacteria, followed by Bacteroidetes. Mir-146, a miRNA associated with the immune system response and upregulation in AD ([@B3]), targeted mainly Firmicutes and Bacteroidetes, with only one hit on Proteobacteria and Actinobacteria, respectively.

A recent study by [@B16] showed that overexpression of miR-146a is linked to an altered gut microbiome in mice. [Supplementary Table S7](#TS7){ref-type="supplementary-material"} lists the exact hits for any protein and any species that could potentially be targeted by hsa-miR-146a-5p. With this in mind, we investigated the taxa that were downregulated upon mir-146a upregulation. Out of the 45 Proteobacteria present in our database, hsa-miR-146a-5p targeted exactly 1 species, *Desulfovibrio* sp. A2, on one protein, the chromosomal replication inhibitor protein *DnaA*. Within the seven Prevotellaceae, *Prevotella salivae* DSM was targeted on the diguanylate cyclase. Parasutella was not targeted at all, since this species was not contained in our gut database. According to [@B16], overabundant taxa were Alistipes, Blautia, Coprococcus and Ruminococcus. For this list of taxa, no targets were predicted for hsa-miR-146a-5p. In conclusion, we found two potential hits on taxa that were downregulated and none on taxa that were upregulated in [@B16] given our genomic database.

[Figure 8](#F8){ref-type="fig"} highlights two very interesting miRNAs, namely hsa-miR-1226 and hsa-miR-4767, which were selected due to their high number of potential target sites reported by miRanda (see section "Crosstalk Between miRNA and Microbiome Composition").

![Number of hits per phylum from miRNAs with the largest target matching. In **(A)**, the hit counts of hsa-miR-1226 per phylum are given, in **(B)** the number of targeted regions of hsa-miR-4767 counted for different phyla. The legend can be found at the bottom. The colors refer to different phyla.](fnins-13-00113-g008){#F8}

hsa-miR-1226 was predicted to have in total 1109 matches whereas hsa-miR-4767 had 683 hits. Interestingly, the latter had an unexpected high amount of 203 hits on *Streptomyces sparsogenes*, accounting for almost one third of the total amount of hits. In both cases, highly targeted phyla were Firmicutes as well as Proteobacteria. [Supplementary Table S6](#TS6){ref-type="supplementary-material"} lists the GO-terms for the selected miRNAs.

Finally, we were interested in putative targets hits on serine proteases. Bacterial HTRA serine proteases have been implicated to play a role in the cleavage of the amyloid precursor protein. Their inhibition causes β-amyloid to accumulate in a culture of astrocyte cells ([@B25]). A first examination revealed two hits on serine proteases in *Lactobacillus antri* and *Flavonifractor plautii* by hsa-miR-664a-5p and hsa-miR-1248, respectively.

Discussion
==========

The search for a cure for neurodegenerative diseases related to protein misfolding such as AD and PD has also led to studies of the gut microbiome and its potential dysregulation. Different studies have demonstrated a connection between the etiology of AD or PD and microbiome alterations ([@B9]; [@B70]). However, the question still remains if and how exactly the host communicates with its internal gut microbiota. A novel and interesting link between host and bacteria was demonstrated by [@B42], who showed that miRNAs from the host might be able to enter bacterial cells and downregulate the expression of bacterial target sequences ([@B42]). Additionally, sequences as short as miRNAs and acting like miRNAs have been naturally found in bacteria ([@B50]), giving further evidence that small RNAs of this size might be active in bacteria. We therefore hypothesized the existence of a crosstalk between microRNAs commonly associated with AD or PD in humans and target sites on bacterial genomes within the human gut metagenome.

Another potential fit for this size requirement are external guide sequences that mediate cleavage by RNAse P ([@B12]). These sequences consist of about 13 to 19 nucleotides complementary to their target site and possess a 3'RCCA nucleotide signature necessary for the cleavage. The only miRNA showing hits and meeting these criteria was hsa-miR-770-5p.

We screened a broad initial dataset of over 300 miRNAs in order to gain a detailed overview over potential interactions between miRNAs and the gut metagenome. The first target scan on gut bacterial genomes for miRNAs involved in AD and PD revealed hits for almost all of the microRNAs investigated in this study, resulting in a plethora of potential interactions.

The sheer volume of interactions predicted by miRanda made it necessary to further reduce the set of targets. This was accomplished by focusing on all hits on bacterial pathways that were assumed relevant in AD and/or PD as well as a core set of miRNAs prominently highlighted in previous studies for their involvement in the microbiome in AD/PD.

The initial results of the target screen made evident that some miRNAs target multiple proteins. This went as far as 1109 predicted hits on protein IDs for hsa-miR-1226-5p. While some of these hits may certainly be false positives, miR-1226-5p was among the miRNAs investigated in [@B42], where it upregulated the growth of *E. coli*. In the same vein, the miRNAs hsa-miR-1183, hsa-miR-4767, hsa-miR-3916, hsa-miR-3180-5p, hsa-miR-1248, hsa-miR-1301-3p, hsa-miR-378c, hsa-miR-1538, hsa-miR-671-5p and hsa-miR-939-5p show promise for future investigations. Each one had over 200 hits of protein identifiers. These could either be spurious hits on repetitive sequences, devoid of any functional meaning, or hits on conserved protein stretches, enabling a single miRNA to target a functional class of proteins over a broad array of species. For eukaryotes it is known that particular miRNA can target several proteins connected in one pathway and that some miRNA families are highly conserved ([@B34]).

Since we performed only an *in silico* scan for miRNA hits on bacterial reference genomes, any detected target requires validation. At the present time, the necessary circumstances that have to be met for a human miRNA to be effective in bacteria are unclear. Properties like target seed site conservation are well known features in eukaryotic miRNAs. If and how this feature might be present in miRNA hits on bacterial sequences, remains to be seen ([@B18]).

Moreover, data regarding fecal miRNA are lacking for AD and PD compared to data for blood and other biofluids and tissues. While it is possible to separate the miRNAs into groups of up- or down-regulated, this might be misleading for several reasons. Due to the lack of data, we did not investigate a single study containing fecal miRNA in AD or PD. Therefore, we do not know if the composition differs between body sites. Even within the same body fluids, different studies showed discordant results. Since it is unclear how miRNAs are exactly imported into and processed within bacteria, selective import might change the ratios of the relevant miRNAs.

As the next step, bacterial pathways and protein cascades with a known involvement in AD or PD were searched. It needs to be mentioned at this point that we only considered the identifiers that could be mapped to KEGG Pathways, as well as some manual exceptions. This includes the lipopolysaccharide biosynthesis. Lipopolysaccharides (LPS) of *E. coli* are known to be elevated in the brain of patients with AD. Furthermore, it has been hypothesized that gut derived LPS are able to traverse the intestinal barrier and travel to the brain. LPS derived from gram negative bacteria colocalises with plaques. Additionally, LPS levels are elevated in the bloodstream of AD patients. This pattern fits well with other studies attesting a link between neuroinflammation and AD ([@B75]; [@B74]). In PD, abnormal levels of an LPS-binding protein were found to be a biomarker for both gastrointestinal inflammation and PD ([@B53]).

The next pathway we evaluated was biofilm formation. Biofilm formation leads to a multitude of functional adaptations for the bacteria. Bacteria are able to secrete numerous functional amyloids, among them Curli, Fap, HpaG and FUBA. With respect to the etiology of AD and PD, it is known that bacterial amyloids are able to propagate amyloid formation *in vivo*. This is supported by rodent studies, where rats that were fed with bacterial amyloids showed enhanced alpha synuclein formation in the brain. This leads to the speculation that biofilm components from the gut microbiota are able to cross-seed to the brain, where they induce amyloidogenesis ([@B45]; [@B10]; [@B13]). More indirect links between biofilm formation and pathogenesis are connected to increased cell adhesion, increased virulence contributing to "leaky gut" and a general weakening of endothelial barriers, observed as well in AD as in PD ([@B62]; [@B20]).

Secretion across lipid membranes is linked to virulence and host immune evasion ([@B26]). Especially with respect to AD, there is a paradigm shift toward latent chronic infection as a main cause for the disease ([@B21]). Coincidentally, one of the first validated functions for a micro-RNA-sized RNA in bacteria was regulating the virulence of said bacteria ([@B50]).

Microbiome dysbiosis in general has been previously recognized in both, AD and PD, and there are several studies, that found different abundances of bacteria between cases and controls through the analysis of fecal 16S rRNA ([@B70]; [@B55]; [@B78]). Some of the species mentioned here were regrettably not present in our genomic database, but, for example, Ruminococcaceae had target site predictions on all of their 12 members in our collection of bacterial genomes. That differential expression of a miRNA, in principle, can alter bacterial abundance has been shown by [@B16], who knocked out miR-146 in mice. If the miRNA-microbiome crosstalk should prove true, it would be definitively worth to investigate further whether the targeting miRNAs have an influence on the species composition of the microbiome by regulating bacterial transcription.

For future studies an *in vivo* validation of putative hits is necessary. Furthermore, since most known bacterial small RNAs are \>50--200 nucleotides ([@B11]), considering longer transcripts might provide further insights. In addition, other classes of small RNAs such as tRNA fragments, which are known to be associated to regulatory pathways in other species, could be considered.

Conclusively, our *in silico* target screen found several miRNAs that may represent key regulators in bacterial pathways relevant to AD or PD. If the human miRNAs should prove to be effective in regulating bacterial transcription, this could lead to several new insights regarding both the microbiome host interaction and the treatment of neurodegenerative diseases. As such, the microbiome-miRNA crosstalk might contribute to the idea of what constitutes a "healthy microbiome," beyond the mere abundance of bacterial taxa toward differential regulations of global pathways. Moreover, there are currently several miRNAs undergoing clinical studies for their use as therapeutics for example against cancer or hepatitis ([@B60]). Thus, the miRNAs might be used as a therapy option to revert the microbiome to a desired state. This may even be applied years before the disease breaks out, so as to keep the pathological changes beyond a threshold level in order to prevent the outbreak of the disease altogether.

Data Availability
=================

Publicly available datasets were analyzed in this study. This data can be found here:

> <https://exrna-atlas.org/exat/publicAnalysis/DESeq2/KJENS1_ADPD_PD_VS_CONTROLS_CSF>

> <https://exrna-atlas.org/exat/publicAnalysis/DESeq2/KJENS1_ADPD_AD_VS_CONTROLS_SERUM>

> <https://exrna-atlas.org/exat/publicAnalysis/DESeq2/KJENS1_ADPD_AD_VS_CONTROLS_CSF>

> <https://exrna-atlas.org/exat/publicAnalysis/DESeq2/KJENS1_ADPD_AD_VS_PD_SERUM>

> <https://exrna-atlas.org/exat/publicAnalysis/DESeq2/KJENS1_ADPD_AD_VS_PD_CSF>

> <https://exrna-atlas.org/exat/publicAnalysis/DESeq2/KJENS1_ADPD_PD_VS_CONTROLS_SERUM>

ERCC: [@B1] -- Original data can be found under phs000727.v1.p1 in dbgap.
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Plots of the most interesting miRNAs and the GO-terms that they are targeting. The additional tables help to see which function the GO-term has.
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Exact hits for any protein and any species that could potentially be targeted by hsa-miR-146a-5p.
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